Ankle & Foot Pain —
Causes & PEMF Protocols.

June 2026 · 11 min read · Clinical Guide

The Scale of Foot and Ankle Pain in the Philippines

The foot bears 1.5–2.5× body weight with every step. In a country where 72% of the workforce is engaged in standing occupations (retail, agriculture, healthcare, domestic work), chronic foot and ankle pain is among the most prevalent and underserved musculoskeletal complaints. An estimated 4.2 million Filipino adults currently experience clinically significant foot or ankle pain. Of these, fewer than 15% receive structured physiotherapy — the rest manage with rest, over-the-counter analgesics, or no treatment at all.

Pathology 1 — Plantar Fasciitis (35% of All Foot Pain)

Plantar fasciitis is the most common cause of heel pain, resulting from micro-tears and degenerative changes at the origin of the plantar fascia at the calcaneus. It affects approximately 2 million people in the Philippines and accounts for roughly 1 in 10 physiotherapy referrals. Classic presentation: stabbing heel pain on the first step in the morning (post-static dyskinesia), VAS 6–9/10 at onset, improving with walking but worsening after prolonged standing.

PEMF Evidence for Plantar Fasciitis

• PMID 22297104 (J Foot Ankle Surg, 2012): randomized, double-blind, placebo-controlled trial, n=70, wearable PRFE device worn overnight — 40% reduction in first-step morning pain at day 7 vs. 7% on placebo (p=0.03); the evening-pain difference was not significant.
• PMID 40378087 (J Am Podiatr Med Assoc, 2025): 12-week case series, no control group — mean plantar fascia thickness −34% on ultrasound, FADI +46%. The often-quoted comparison against steroid injection uses historical controls from other studies, not a randomized arm.
• Protocol: 50 Hz, 25 mT, 30 minutes daily for 4–6 weeks

Pathology 2 — Achilles Tendinopathy

Achilles tendinopathy (chronic degeneration of the Achilles tendon) affects athletes and sedentary patients alike. Prevalence: approximately 2.35 per 1,000 in the general population, rising to 40–50% lifetime incidence in recreational runners. In the Philippines, the combination of flip-flop footwear, uneven terrain, and high rates of diabetes (which weakens tendon structure) creates an elevated-risk environment.

PEMF Evidence for Achilles Tendinopathy

• PMC7093940: PEMF promotes collagen fiber alignment and tenocyte proliferation in degenerative tendons, accelerating structural repair
• Tendon-specific parameters: 15–25 Hz, 10–15 mT, 20–30 minutes per session, minimum 8-week course
• Clinical outcome: VAS reduction from 6.2 to 2.8, VISA-A score improvement +22 points at 8 weeks

Pathology 3 — Ankle Osteoarthritis

Post-traumatic ankle OA (following ankle fractures or repeated sprains) and primary ankle OA share the same cartilage degradation pathway as knee and hip OA — and respond to the same PEMF chondroprotective mechanisms. Ankle OA is estimated to affect approximately 1% of the adult population, with Filipino patients presenting on average 5–8 years after the initial injury.

PEMF Evidence for Ankle OA

• PMC9110240 meta-analysis parameters apply: pain SMD = 0.71, stiffness SMD = 1.34, function SMD = 1.52
• Proteoglycan synthesis +42%, collagen II upregulation (PMC3518856)
• Protocol: 25–50 Hz, 15–30 mT, 30 minutes, 3x/week for 8–12 weeks

Important context on these figures. The effect sizes above come from Tong et al., 2022 (PubMed 35586276 / PMC9110240) and are accurately quoted — but they are not the whole literature. A more recent systematic review and meta-analysis — Chang, Lin & Huang, Medicina, 2026 (PubMed 42075549), 9 RCTs and 457 knee-OA patients — found no significant improvement in VAS pain or total WOMAC at one month, rated the overall risk of bias across the included trials as high, and concluded that although some improvements are statistically significant they “may not reach thresholds for clinical meaningfulness”. Separately, a 2026 double-blind sham-controlled trial (PubMed 41588476, n=60) measured femoral cartilage thickness and minimum joint space width out to 12 months and found no difference from sham. PEMF relieves symptoms; it does not rebuild the joint. We publish both sides, because a clinic that is blindsided by the negative trial later is a clinic that stops believing the positive one.

Pathology 4 — Ankle Sprains & Chronic Instability

Ankle sprains are the most common sports injury in the Philippines. Approximately 23,000 ankle sprains occur daily globally; about 40% progress to chronic ankle instability (CAI) if undertreated. CAI is defined as recurrent giving-way episodes with persistent pain and proprioceptive deficit more than 12 months after the initial sprain.

PEMF Evidence for Ankle Sprains

• PEMF accelerates ligament healing via fibroblast proliferation and collagen deposition
• Reduces acute post-sprain edema and pain within 48–72 hours of treatment initiation
• Acute protocol: 50–100 Hz, 10–20 mT, 20 minutes, 2x/day for 5–7 days
• Rehabilitation protocol: 25 Hz, 15 mT, 30 minutes, 3x/week for 4–6 weeks
• Study: acute ankle sprain cohort (n=48) — return to sport 8.2 vs 13.6 days (PEMF vs conventional), p=0.008

Pathology 5 — Tarsal Tunnel Syndrome

Tarsal tunnel syndrome (TTS) is the foot equivalent of carpal tunnel — compression of the posterior tibial nerve beneath the flexor retinaculum at the medial ankle. Presentation: burning, tingling, and paresthesia along the plantar surface of the foot, often worsening at night and with prolonged standing. TTS prevalence rises sharply in diabetic patients (concurrent peripheral neuropathy) and those with flat-foot deformity (pes planus), both common in the Philippines.

PEMF Evidence for Tarsal Tunnel Syndrome

• PEMF nerve regeneration mechanism: increases nerve conduction velocity, reduces intraneural edema, promotes Schwann cell activity
• Parallel evidence: carpal tunnel (median nerve) — PEMF vs. ultrasound RCT (PMC5144749, n=40): PEMF superior across all endpoints (VAS, sensory latency, motor latency, conduction velocity, grip strength), all p<0.05
• TTS protocol: 50 Hz, 8–10 mT, 30 minutes, 3x/week for 4–6 weeks; applicator positioned over the medial malleolus

Pathology 6 — Morton's Neuroma

Morton's neuroma is a benign perineural fibrosis of the common digital nerve (usually between the 3rd and 4th metatarsal heads), causing sharp, burning forefoot pain with weight bearing. It affects 3–4 times more women than men (narrow footwear) and accounts for approximately 1 in 30 foot pain presentations in physiotherapy.

PEMF Evidence for Morton's Neuroma

• PEMF mechanism: reduces perineural inflammation, decreases fibrotic adhesion formation, modulates neuropathic pain signaling
• Protocol: 15–25 Hz, 10 mT, 20–30 minutes, 3x/week for 6 weeks
• Combined with low-level laser therapy (LLLT): synergistic effect — VAS from 7.2 to 2.4 at 6 weeks in a combined modality case series (n=22)

Treatment Parameters by Condition

Contraindications

Absolute contraindications: active cardiac pacemaker or implanted defibrillator, pregnancy (avoid direct uterine exposure), active epilepsy, active malignancy in the treatment zone. Relative: metallic surgical hardware in the foot (e.g., fixation screws post-fracture) — discuss with the surgeon; PEMF can often be applied at adjacent anatomy.

The Business Case — Why Foot Pain Patients Fill Clinics

Foot and ankle pain patients share two high-value clinical traits: they typically require multi-session courses (6–12 weeks) and they are self-referred or referred by sports medicine physicians, creating a direct-to-clinic patient flow without GP bottlenecks. At ₱2,000/session × 18 sessions, a full ankle OA patient course generates ₱36,000 in revenue. With 70+ Israeli clinics (population: 9M) now expanding to the Philippines, PainFree's operational model includes clinic-level patient acquisition support, outcome tracking tools, and device lease terms that allow breakeven at as few as 15 sessions per week.